Abstract:OBJECTIVE To investigate the role and mechanism of action of fibroblast growth factor-21 (FGF-21) in reducing triglyceride (TG) in the in vitro and in vivo models of nonalcoholic fatty liver disease (NAFLD). METHODS (1) A mixture of free fatty acids was used to establish a model of steatosis in L02 cells, and the cells were treated with various concentrations of FGF-21 or fenofibrate. Twenty-four hours later, oil red O staining was performed to observe the degree of steatosis, and intracellular TG content was determined. RT-PCR and Western blot were applied to measure the mRNA and protein expression of sterol regulatory element-binding protein-1c (SREBP-1c). (2) High-fat diet was used to establish a mouse model of steatosis, and these mice were intraperitoneally injected with FGF-21 or fenofibrate. Eight weeks later, whole blood and liver samples were collected, and HE staining was performed to observe steatosis. Meanwhile, the serum levels of TG, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured, and TG content in the liver was also measured. One-way analysis of variance was used for comparison of data between multiple groups, and the least significant difference t-test was used for comparison between any two groups. RESULTS (1) Compared with the control group, the model group showed significant steatosis, with significant increases in intracellular lipid droplets and TG content (t = -20.57, P < 0.01), while FGF-21 reduced the number of intracellular lipid droplets and TG content (F = 98.16, P < 0.01) in a dose-dependent manner. In addition, the model group had significantly increased mRNA and protein expression of SREBP-1c compared with the control group (t = -10.73 and -0.1006, both P < 0.01), while FGF-21 down-regulated the mRNA and protein expression of SREBP-1c (F = 161.35 and 36.72, both P < 0.01). (2) Compared with the mice in the control group, those in the model group showed significant steatosis and had significant increases in serum TG level and TG content in the liver (t = -18.84 and 15.71, both P < 0.01). FGF-21 relieved hepatic steatosis and reduced the serum TG level and TG content in the liver (t = 18.11 and 9.46, both P < 0.01). Moreover, FGF-21 reduced the serum levels of ALT and AST in NAFLD mice (t = 25.93 and 12.50, both P < 0.01). CONCLUSION FGF-21 can inhibit the synthesis of TG through suppressing the expression of SREBP-1c, which further confirms the potential therapeutic effect of FGF-21 in the treatment of NAFLD. This may provide new ideas for the treatment of NAFLD.

Concentrated fish oil ameliorates non-alcoholic fatty liver disease by regulating FGF21-adiponectin axis

The effects of fish oil plus vitamin D 3 intervention on non-alcoholic fatty liver disease: a randomized controlled trial

Effects of Dietary Supplementation of Fish Oil Plus Vitamin D3 on Gut Microbiota and Fecal Metabolites, and Their Correlation with Nonalcoholic Fatty Liver Disease Risk Factors: a Randomized Controlled Trial

The effects of fish oil plus vitamin D3 intervention on non-alcoholic fatty liver disease: a randomized controlled trial

Elevated Serum Phosphatidylcholine (16:1/22:6) Levels Promoted by Fish Oil and Vitamin D3 Are Highly Correlated with Biomarkers of Non-Alcoholic Fatty Liver Disease in Chinese Subjects.

Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial

Fatty Acid and Non-Alcoholic Fatty Liver Disease: Meta-analyses of Case-Control and Randomized Controlled Trials.

Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway

[Role and mechanism of action of fibroblast growth factor-21 in reducing triglyceride in nonalcoholic fatty liver disease].

N-3 Polyunsaturated Fatty Acids in Phospholipid or Triacylglycerol Form Attenuate Nonalcoholic Fatty Liver Disease Via Mediating Cannabinoid Receptor 1/adiponectin/ceramide Pathway.

Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis

Effects of dietary supplementation of fish oil plus vitamin D3 on gut microbiota and fecal metabolites, and their correlations with nonalcoholic fatty liver disease risk factors: a randomized controlled trial

Flaxseed Oil Containing Flaxseed Oil Ester of Plant Sterol Attenuates High-Fat Diet-Induced Hepatic Steatosis in Apolipoprotein-E Knockout Mice

FGF21 Ameliorates Nonalcoholic Fatty Liver Disease by Inducing Autophagy

Fibroblast Growth Factor 21 Levels Are Increased in Nonalcoholic Fatty Liver Disease Patients and Are Correlated with Hepatic Triglyceride

Low‐molecular‐weight fucoidan and high‐stability fucoxanthin decrease serum alanine transaminase in patients with nonalcoholic fatty liver disease—A double‐blind, randomized controlled trial

[Improvement Situation on Indexes of the Zebrafish Disease Model of Non-Alcoholic Fatty Liver Disease with FGF21 Analogues].

Epigallocatechin-3-gallate ameliorates hepatic damages by relieve FGF21 resistance and promotion of FGF21–AMPK pathway in mice fed a high fat diet

Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease

Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice

Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway